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Abstract 
Background: Cardiac surgery especially in small children is associated with 
a marked decrease in thyroid hormone levels consistent with the phenomenon 
referred to as Sick Euthyroid Syndrome (SES). The purpose of the present 
study was to determine if oral triiodothyronine could reduce the length of ICU 
stay, vasoactive inotropic score (VIS), and promote ejection fraction in infants 
and children undergoing cardiac surgery with CPB. 
Materials and Methods: In a double-blind clinical trial, one hundred and 
twenty children aged 6 to 60 months and scheduled for different types of 
cardiac surgery with CPB, were randomized into two groups to receive either 
2 mcg/Kg triiodothyronine (trial group) or 5% dextrose water (placebo group), 
immediately after anesthesia and 24 hours after surgery. The perioperative 
serum thyroid hormone levels and hemodynamic variables were determined. 
The intubation time, ICU stay length, ICU inotropic use, and cardiac ejection 
fraction was recorded. 
Results: The basic demographic data were comparable in two groups. No 
significant side effects or adverse reactions were seen due to hormone therapy. 
Intubation time, ICU stay, and VIS values were significantly shorter between 
the two groups. 
Conclusion: In children undergoing cardiac surgery with CPB, perioperative 
oral small-dose triiodothyronine therapy could improve clinical indices of 
perioperative care. 
Keywords: Pediatric congenital cardiac surgery, Sick Euthyroid Syndrome, 
Thyroid hormone replacement therapy 
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Introduction 
Cardiac surgery produces a generalized systemic 
inflammatory reaction, resulting in increased 
postoperative complications (1-3). Cardiac surgery 
with or without cardiopulmonary bypass, mainly in 
small children, is associated with a marked decrease in 
thyroid hormone levels consistent with the 
phenomenon referred to as Sick Euthyroid Syndrome 
(SES) (4-9). Thyroid Hormones (THs) have a 
cardioprotective role through direct or indirect actions 
at the level of the myocytes, the interstitium, and the 
vasculature. THs have also an antiapoptotic effect on 
myocytes. 
The contractile apparatus of the cardiac 
myocyte contains the α and β myosin heavy chains, 
which are positively and negatively regulated by T3, 
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respectively. Cardiac contractility is further regulated 
by several important cardiac proteins (1, 3), including 
the Sarco/endoplasmic reticulum Ca2+-ATPase 
(SERCA2) and its inhibiting counterpart 
phospholamban (PLB). SERCA2 is positively 
regulated by T3, whereas PLB is negatively regulated. 
Together, they are responsible for the kinetics of 
calcium ion influx into (and subsequent efflux from) 
the sarcoplasmic reticulum. This lusitropic effect of 
TH is a characteristic of T3 regulation of myocyte 
contractility (2, 9).  
The present study aimed to determine whether 
in pediatric congenital surgeries oral triiodothyronine 
could reduce the length of stay in ICU and hospital, 
vasoactive inotropic score (VIS), pump, and clamp 
time, and promote ejection fraction in infants and 
children undergoing open-heart surgery using CPB. 
 
Methods 
After institutional ethics committee approval 
(IR.SBMU.MSP.REC.1397.609), and Iranian Clinical 
Trial Database registration (IRCT registration number: 
IRCT20180502039507N1), children aged 6 to 60 
months and scheduled for open-heart surgery with 
CPB under general anesthesia were recruited from 
Modarres Hospital, Shahid Beheshti University of 
Medical Sciences in Tehran (April 2018-February 
2019). Informed written consent was obtained from the 
parents by the principal investigator. 
One hundred and twenty children were enrolled 
in this study. Of them, 48 had ventricular septal 
defects, 28 atrial septal defects, 15 ventricular septal 
defects combined with atrial septal defects, and 21 had 
tetralogy of Fallot, 3 aortic stenoses, and 5 had single 
ventricle anomaly. 
Exclusion criteria were abnormal baseline 
thyroid function, thyroid diseases and other endocrine 
diseases, use of drugs affecting thyroid function, and 
preoperative use of inotropic drugs for circulatory 
support. 
Patients were randomized into 2 groups of equal 
size to receive the following treatments in a double-
blind manner: placebo (control group) and trial group. 
Six hours before surgery, the patients were randomly 
assigned to receive either triiodothyronine or placebo. 
Cases assigned to triiodothyronine received an oral 
dose of 2 mcg/kg of body weight. The patients in the 
placebo group received a 5 percent dextrose solution. 
Repeated doses were administered immediately after 
anesthesia (via a gastric tube) and 24 hours after 
surgery. 
Samples of arterial blood, for determination of 
serum total T3, total T4, and TSH concentrations (by 
radioimmunoassay method) were checked one day 
before surgery, 24 and 48 hours after surgery. 
All physicians and nurses involved in the 
patients' care were unaware of the treatment 
assignments, and except for the administration of the 
study drug, care during and after surgery did not differ 
in the two groups. 
The operation was performed by a single cardiac 
surgery team using a standardized protocol for 
anesthesia and surgery. In the operating room, at first, 
5-lead electrocardiogram, invasive blood pressure, 
central venous pressure, cerebral oximetry, and pulse 
oximeter were monitored. 
After routine preoxygenation, anesthesia was 
induced. Neuromuscular blockade was provided. After 
intubation, the lungs were ventilated with intermittent 
positive pressure ventilation, with a tidal volume of 8 
to 10 ml/kg, a respiratory rate of 18-25 breaths/min, 3-
5 cm water of PEEP, an inspiratory/expiratory ratio of 
1:2, FiO2 equal to 40% to 60% and an oxygen flow of 
2.5 l/min. 
All children received standardized surgical and 
CPB management. Mild hypothermia (30–34 °C) was 
used for performing the procedures. During CPB, we 
maintained hematocrit at 24% to 28%. Besides, the 
cold blood cardioplegia solution (4 °C) was perfused to 
provide cardioprotection. The duration of aortic clamp 
and CPB were recorded. After performing the surgical 
procedure and systemic rewarming, the patients were 
transferred to ICU, where standardized institutional 
postoperative protocols were applied. 
The perioperative serum thyroid hormone levels 
and hemodynamic variables were assessed. Intubation 
time, ICU stay duration, and the use of inotropic drugs 
in ICU were recorded. VIS was used to evaluate the 
inotropic need for cardiovascular support in children 
after the surgery (9). However, the inotropic support 
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was measured using the following formula; where VIS 
was defined as Vasoactive Inotropic Support:  
VIS = dopamine (mcg/kg/min) + dobutamine 
(mcg/kg/min) + 100 x epinephrine (mcg/kg/min) + 100 
x norepinephrine(mcg/kg/min) + 10 x milrinone 
(mcg/kg/min) + 10,000 x vasopressin (mUnits/kg/min) 
The patients in the trial group received 
triiodothyronine immediately after anesthesia and 24 
hours later. Postoperative care including weaning and 
ICU discharge were based on the standard institutional 
protocols. 
We compared intubation time, ICU stays, and 
VIS in the first postoperative 24 hours, cardiac ejection 
fraction; while we assessed total T3 (TT3), total T4 
(TT4), and TSH levels during postoperative 48 hours. 
Data were analyzed using Statistical Package 
for Social Sciences, version 14 (SPSS Inc., Chicago, 
IL, USA). The correlation between quantitative data 
was tested using a T-test; however, P values less than 
0.05 were considered statistically significant. 
 
Results 
The demographic characteristics and clinical data of 
the cases are shown in Table-1. There were no 
significant differences in age (P value=0.43), weight (P 
value=0.37), duration of CPB (P value=0.32), and 
aortic clamp time (P value=0.36) between groups. 
In both groups, the mean serum T3, T4, and 
TSH concentrations were in the normal range before 
surgery. Serum T3, T4, and TSH levels on the first and 
second postoperative days were not significantly 
different in 2 groups (Table 2). 
The median intubation time and duration of ICU 
stay were 17.7 hours and 6 days in the control group, 
respectively, 9.8 hours and 5 days in the trial group. 
VIS was 17.38±5.63 and 11.48±5.22 in the control and 
trial group, respectively. There were significant 
differences in ICU stay length (P value= 0.02), VIS (P 
value=0.0001) and intubation time (P value=0.0001) 
between groups (Figure 1, 2, and 3). 
 
Discussion 
To the best of the authors’ knowledge, this is the first 
clinical trial study of triiodothyronine therapy effect in 
children undergoing congenital cardiac surgery in Iran. 
Previous studies have shown that the metabolism of 
thyroid hormones was altered in children after 
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congenital heart surgery. As a matter of fact, it is CPB 
that results in a significant and persistent depression of 
circulating thyroid hormones (10-13). Considering this 
concept, it would be rational to supply these hormones 
perioperative to improve patients’ postoperative 
course.  
As oral hormone therapy is very simple, 
available, and inexpensive, regarding the selection of 
route of administration to be effective, either orally or 
parenterally, Choi et al (14, 15) demonstrated that oral 
T3 therapy significantly attenuated the postoperative 
decline in the serum concentration of T3. Marwali and 
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colleagues (16) concluded that hormone 
supplementation by an oral dose of 0.5 mcg/Kg every 
12 hours for three days could maintain total and free 
T3 levels within normal limits after pediatric open-
heart surgery.  
It seems that the degree of thyroid hormone 
derangement is closely related to the difficulties of 
postoperative management. Dagan et al (17) have 
shown that in neonates treated with high doses of 
inotropes, the level of free T4 was significantly lower 
than patients with low doses of inotropes and this 
decrease persisted for a longer period. 
The effect of thyroid hormone supplementation 
on the postoperative course of pediatric surgical 
patients was studied in previous researches. Although 
most of them proved its beneficial effect, some did not 
show any statistically significant result. A study by 
Haas et al (18) reported that thyroid hormone 
Table 1: Demographic and clinical data in two groups. Data are expressed as mean ± SD; n=60 in each group. 
variable Trial group Control group P value  
Gender 
(F/M) 
29/31 32/28 0.2 
Age (month) 24.2±13.1 22.3±13.1 0.43 
Weight (Kg) 11.2±5.4 10.9±4.7 0.37 
Intubation time (hour) 9.8±4.9 17.7±8.8 0.00 
ICU stay (day) 5.1±2.2 6.08±2.36 0.02 
Duration of CPB (min) 92.73±30.62 102.4±33.17 0.32 
Aortic Clamp Time (minutes) 48.75±24.73 56.08±21.89 0.36 
Vasoactive Inotropic Score: 
VIS 
11.48±5.22 17.38±5.63 0.0001 
Ejection Fraction (%) 49±4 41±3 0.16 
 
Table 2: Serum of thyroid hormone levels in 2 groups. TSH (mIU/l) T4 (mcg/dl); T3 (ng/dl). Data are expressed as means ± SD; 
n=60 in each group. 
variable Trial group Control group P value 
TSH FIRST (1) 2.55±1.24 2.3±1.7 0.47 
TSH SECOND (2) 2.2±1.2 2.2±1.2 0.11 
TSH THIRD (3) 2.3±1.4 2.1±.89 0.42 
T3 FIRST (1) 1.2±1.44 1.2±.3 0.24 
T3 SECOND (2) 1.5±.44 1.3±.36 0.13 
T3 THIRD (3) 6.1±1.4 1.4±.67 0.07 
T4 FIRST (1) 9.4±2.1 8.49±3.3 0.059 
T4 SECOND (2) 8.07±2.4 8.04±2.6 0.25 
T4 THIRD (3) 8.44±1.8 9.12±1.9 0.05 
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replacement therapy could be a desirable option in 
terms of mortality and morbidity decrease, especially 
in high-risk pediatric cardiac patients. Aaron et al (19) 
proved that supplementation with triiodothyronine 
could achieve three important goals namely, 
improvement of hemodynamic function, reduction of 
inotrope usage, and shortening the duration of 
mechanical circulatory support. On the other, it is 
demonstrated that thyroid hormone replacement 
therapy is not necessary for patients under cardiac 
surgery, as this Sick Euthyroid Syndrome will recover 
spontaneously within one week (20). It has been 
concluded that with oral levothyroxine supplement 
therapy, the time to extubation and length in ICU and 
hospital stay would be decreased (21). Although this 
difference was just clinically, not statistically 
significant. Our study proved the effect of 
perioperative oral triiodothyronine therapy on the 
reduction of VIS, intubation time, ICU stays, and 
hospital stay, which is in agreement with the 
previously mentioned studies. 
Regarding the effect of the patient’s age, there 
is some emphasis on the more obvious benefit of 
hormone therapy for infants and neonates. In other 
studies, intravenous triiodothyronine supplementation 
has been demonstrated safe, resulting in better clinical 
outcome scores and more rapid achievement of 
negative fluid balance in a group of neonates 
undergoing Norwood operation or repair of the aortic 
arch; however, there was no significant improvement 
in postoperative cardiac index (22-24). 
A study by Portman et al (25) reported that 
triiodothyronine therapy in Infants undergoing 
ventricular septal defect or tetralogy of Fallot repair 
could enhance cardiac function reserve. This effect was 
through the improvement of myocardial oxygen 
consumption. A multicenter randomized trial (TRICC 
trial) proved that triiodothyronine supplementation 
was safe in infants and children after cardiopulmonary 
bypass and could result in clinical advantages in 
patients younger than 5 months (24). This is not in 
accordance with our study. The range of our patients 
was from six to sixty months and we could show the 
significant effect of T3 supplementation beyond 
infancy. 
To reach to a briefing, our experience in 
children undergoing cardiac surgery with CPB 
suggests that preoperative and postoperative short-
term oral small-dose triiodothyronine treatment can 
reduce intubation time, VIS, ICU stay, and hospital 
stay. 
At least, part of the oral triiodothyronine effect 
in reducing intubation time, VIS, ICU stay, and 
hospital stay can be attributed to the cardioprotective 
effects of thyroid hormones. The most important 
shortcoming of this study was the limited sample size. 
The inclusion of both cyanotic and acyanotic patients 
might have also affected our results. 
 
Conclusion 
In the present study, we found a relationship between 
thyroid hormone replacement therapy and reducing the 
length of ICU stay, intubation time, and VIS in patients 
undergone CPB. We recommend perioperative 
triiodothyronine supplementation in pediatric 
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